How to Get Addyi (Flibanserin) in North Dakota

What Is Addyi and Why Does It Require a Special Prescribing Process?

Addyi (flibanserin) is the only FDA-approved non-hormonal oral medication for hypoactive sexual desire disorder in premenopausal women. It works centrally, decreasing serotonin activity and modestly increasing dopamine and norepinephrine in the prefrontal cortex, which is a different mechanism from any hormonal therapy. Because of a well-documented risk of hypotension and syncope when combined with alcohol or strong CYP3A4 inhibitors, the FDA required a Risk Evaluation and Mitigation Strategy (REMS) at approval in August 2015 [1].

The REMS program was simplified in April 2019. Patient enrollment cards are no longer required. Prescribers still must complete a brief online training at the Addyi REMS website and counsel patients on the alcohol restriction before dispensing [1]. Pharmacies that dispense Addyi must also be REMS-certified, which narrows the dispensing options somewhat but does not prevent mail-order fulfillment.

In the BEGONIA trial (N=1,378 premenopausal women), flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo over 24 weeks, with a mean increase of 0.7 SSEs per 28 days versus 0.4 for placebo (P<0.001) [2]. The same trial reported a reduction in distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) of 21.3 points versus 17.1 for placebo [2]. These are modest but clinically meaningful gains for a condition that affects an estimated 8 to 10 percent of premenopausal women in the United States [3].

The FDA label specifies that flibanserin is contraindicated with alcohol, with moderate-to-strong CYP3A4 inhibitors (including fluconazole, ketoconazole, and several antiretrovirals), and in patients with hepatic impairment [1]. North Dakota prescribers, whether in-person or via telehealth, must complete this safety review before sending a prescription.

Who Can Prescribe Addyi in North Dakota?

Any licensed prescriber with REMS certification can write an Addyi prescription in North Dakota. That includes physicians (MD and DO), nurse practitioners (NP), and physician assistants (PA). North Dakota grants NPs full practice authority under North Dakota Century Code § 43-12.1, meaning an NP does not need a collaborating physician to prescribe controlled substances or REMS drugs [4]. PAs in North Dakota operate under a supervision agreement but may independently prescribe under that agreement.

Telehealth prescribing is explicitly authorized in North Dakota under N.D. Admin. Code § 33-03.1-07, provided the prescriber establishes a valid patient-provider relationship. For most telehealth platforms, this means a synchronous audio-video visit before the first prescription is sent, though some platforms use asynchronous intake with a follow-up video call. The prescriber must be licensed in North Dakota or hold an applicable interstate compact license.

The HealthRX clinical team uses a four-step prescribing framework for Addyi in states like North Dakota where both in-person and telehealth pathways are available:

1. Structured intake questionnaire covering HSDD symptom duration (>6 months required by DSM-5 criteria), distress level (FSDS-R score >11 suggested as a clinical threshold), and relationship context.
2. Medication and supplement review for CYP3A4 inhibitors and alcohol use patterns.
3. Synchronous video visit with REMS-mandated alcohol counseling documented in the chart.
4. Electronic prescription sent to a REMS-certified pharmacy, with a 30-day follow-up scheduled.

This framework is consistent with the Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction, which recommends that clinicians screen for relationship distress, mood disorders, and hormonal causes before initiating pharmacotherapy [5].

What Labs Are Required Before Starting Addyi in North Dakota?

No mandatory lab panel is required by the FDA label or REMS program before prescribing flibanserin. The requirement is clinical, not laboratory-based. The FDA label directs prescribers to rule out conditions that could cause low desire secondarily, including hypothyroidism, hyperprolactinemia, and surgical menopause [1].

In practice, most clinicians order a targeted panel. A reasonable baseline includes TSH (to rule out hypothyroidism), prolactin (to rule out hyperprolactinemia causing secondary HSDD), total and free testosterone (low androgen status is a common confounder), and a complete metabolic panel if hepatic impairment is a concern [5]. Liver function testing is not explicitly required by the label but becomes relevant if the patient takes other hepatically metabolized drugs or reports significant alcohol use, since hepatic impairment is a contraindication [1].

One 2020 survey of certified Addyi prescribers published in the Journal of Sexual Medicine found that 68 percent ordered at least a thyroid panel before prescribing, and 54 percent included testosterone levels [6]. Neither is mandatory, but both reduce the risk of treating primary HSDD when a correctable endocrine cause is actually driving the symptom.

North Dakota telehealth platforms can order labs through regional draw sites. LabCorp operates patient service centers in Fargo, Bismarck, Grand Forks, and Minot, and Quest Diagnostics serves several additional ND locations. Results typically return within 48 to 72 hours for a standard hormone panel [7].

How Telehealth Prescribing of Addyi Works in North Dakota

Telehealth for controlled and REMS-restricted medications in North Dakota operates under the same rules that apply nationally post-COVID. The DEA's 2023 proposed telemedicine rules do not classify flibanserin as a controlled substance (it is not a scheduled drug), so it does not face the same prescribing restrictions as buprenorphine or testosterone [8]. A prescriber needs only to be REMS-certified and licensed in North Dakota.

The typical telehealth pathway runs as follows. A patient completes a digital intake form that screens for the DSM-5 criteria for HSDD: low sexual desire present for at least 6 months, marked personal distress, and absence of a better explanatory diagnosis. The clinician reviews this form before the video visit, which generally runs 20 to 30 minutes. During the visit, the clinician confirms the diagnosis, reviews contraindications, documents the required REMS alcohol counseling, and sends the prescription electronically to a REMS-certified mail-order pharmacy.

A 2021 analysis in Telemedicine and e-Health found that telehealth visits for women's sexual health reduced time-to-prescription by a median of 34 days compared with in-person specialist referral pathways in rural states [9]. North Dakota is classified as a primarily rural state by the USDA Economic Research Service, with roughly 60 percent of the population living outside metropolitan areas [10]. That rural distribution makes telehealth access particularly relevant for ND residents who would otherwise need to travel to Fargo or Bismarck for a specialist appointment.

Patients should verify that any telehealth platform they choose holds an active North Dakota prescriber license or operates under the Interstate Medical Licensure Compact. Platforms that prescribe federally but lack ND state licensure cannot legally send prescriptions to North Dakota pharmacies.

North Dakota Pharmacies and 503A Compounding Options

REMS-certified retail and mail-order pharmacies can dispense brand-name Addyi in North Dakota. The list of certified dispensing pharmacies is maintained on the FDA REMS database [1]. Major mail-order options that serve North Dakota include specialty pharmacies affiliated with large PBM networks. The brand-name 100 mg tablet typically retails for approximately $800 to $900 for a 30-day supply without insurance. With a manufacturer savings card from Sprout Pharmaceuticals, commercially insured patients may pay as little as $25 to $99 per month, depending on plan type.

North Dakota also permits 503A compounding pharmacies to prepare flibanserin preparations for individual patients with a valid prescription. A 503A pharmacy compounds patient-specific preparations under state board of pharmacy oversight and is exempt from FDA drug approval requirements for the specific patient preparation, though the compounder must use pharmaceutical-grade API [11]. This pathway can reduce cost substantially. Compounded flibanserin 100 mg capsules from a licensed 503A pharmacy may cost $60 to $150 per month depending on the compounding pharmacy and dispense quantity.

The North Dakota Board of Pharmacy licenses 503A compounding pharmacies and maintains an active licensee database. Patients and prescribers can verify licensure at pharmacy.nd.gov. A key point: the compounding pharmacy must be REMS-certified to dispense flibanserin, even when preparing a compounded formulation, because the REMS obligation attaches to the drug substance, not only the brand product [12].

Shipping timelines from REMS-certified mail-order pharmacies to North Dakota addresses typically run 3 to 7 business days. Some specialty pharmacies offer overnight shipping to ND zip codes for an additional fee. Compounding pharmacies may have a 24 to 48-hour preparation window before shipment.

Prior Authorization Requirements for Addyi in North Dakota

Most commercial insurance plans sold in North Dakota require prior authorization (PA) for flibanserin. The typical PA criteria include a documented DSM-5 diagnosis of HSDD, confirmation that the patient is premenopausal, documentation that low desire causes marked personal distress, and evidence that secondary causes (thyroid disease, depression, relationship factors) have been evaluated or ruled out [13].

Some plans add a step-therapy requirement, which means they may first require a trial of therapy or counseling before approving a medication. The American College of Obstetricians and Gynecologists (ACOG) 2019 committee opinion on female sexual dysfunction states that "cognitive-behavioral therapy and mindfulness-based interventions have evidence for improving sexual desire" and recommends these as adjuncts, not replacements, for pharmacotherapy in HSDD [14]. Documenting that behavioral approaches were discussed, even if not formally trialed, can support a PA submission.

The PA submission generally requires the prescribing clinician to submit a letter of medical necessity, recent lab results ruling out secondary causes, and the patient's FSDS-R or related distress screening score. North Dakota Medicaid does not cover Addyi as of 2025, so Medicaid beneficiaries must pay out of pocket or pursue the 503A compounding route. Medicare Part D similarly does not cover flibanserin because it is classified as a lifestyle drug under Medicare's statutory exclusions [13].

For commercially insured patients whose PA is denied, the standard appeals process applies. A peer-to-peer review call between the prescribing clinician and the plan's medical director resolves approximately 40 to 60 percent of initial denials in women's health categories, based on data reported in a 2022 JAMA Internal Medicine analysis of PA appeals outcomes [15]. The appeal should cite the FDA-approved indication, the patient's FSDS-R score, and any prior non-pharmacological interventions attempted.

Transferring an Existing Addyi Prescription to North Dakota

Patients who relocate to North Dakota with an existing Addyi prescription from another state can transfer that prescription to a REMS-certified pharmacy in North Dakota, provided refills remain on the prescription. Because flibanserin is not a controlled substance, interstate transfer rules that restrict Schedule II through IV drugs do not apply. Any REMS-certified pharmacy licensed in North Dakota can accept a transferred prescription [12].

If the original prescriber is not licensed in North Dakota, refills cannot legally be authorized by that out-of-state prescriber once the patient has established North Dakota as their primary residence. The patient will need a new prescribing relationship with a North Dakota-licensed clinician, either through a local provider or a telehealth platform with ND licensure. Establishing that new relationship typically takes one to two weeks from initial intake to first prescription, based on standard telehealth onboarding timelines [9].

Patients who transfer prescriptions mid-month should confirm with the receiving pharmacy that their REMS certification is active before transfer, to avoid a dispensing delay. The REMS certification database is publicly searchable at the FDA's REMS page [1].

Monitoring and Follow-Up After Starting Addyi in North Dakota

The FDA label recommends evaluating response at 8 weeks. If a patient does not experience a meaningful benefit in SSEs or distress reduction by 8 weeks at the 100 mg nightly dose, flibanserin should be discontinued [1]. There is no dose titration option since 100 mg nightly is both the starting and maximum dose.

Follow-up labs are not required by the label, but checking in on blood pressure is reasonable if the patient reports dizziness or lightheadedness, which occurred in 11 percent of participants in pooled clinical trial data compared with 3 percent on placebo [2]. Syncope was reported in 0.4 percent of flibanserin-treated patients versus 0.2 percent on placebo in those same pooled data [2].

Ongoing telehealth follow-up visits every 3 months are standard practice for continuing REMS-restricted prescriptions. The Endocrine Society guideline on female sexual dysfunction recommends reassessment of treatment goals and distress levels at each visit using a validated tool such as the FSDS-R or the Female Sexual Function Index (FSFI) [5]. A clinically meaningful response is generally defined as a reduction of at least 10 points on the FSDS-R from baseline [16].

Patients who develop a new CYP3A4-inhibiting medication during the course of flibanserin treatment must stop flibanserin at least 2 days before starting the inhibitor, per FDA label guidance, and should contact their prescriber promptly [1].